A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

NCT00831649 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
INDUSTRY
Sponsor class

Stopped The biological effect seen with natalizumab was not sufficient to warrant further development in RA.

Conditions

Interventions

Sponsor

Biogen

Collaborators